Skip to content
    Clinical Trials

    JCM, Vol. 15, Pages 7464: Long-Term Outcomes of Interventional Treatments for Lung Cancer Liver Metastases: Transarterial Chemoembolization and Microwave Ablation

    Vogl et alJournal of Clinical Medicine

    JCM, Vol. 15, Pages 7464: Long-Term Outcomes of Interventional Treatments for Lung Cancer Liver Metastases: Transarterial Chemoembolization and Microwave Ablation
    In a retrospective comparative study spanning 2009 to 2024, researchers evaluated the long-term clinical efficacy and safety of interventional locoregional therapies for lung cancer liver metastases (LCLM). The study analyzed 56 patients (mean age 59.1 ± 9.8 years; 31 men, 25 women) categorized into two cohorts: 26 patients with 49 tumors treated exclusively with transarterial chemoembolization (TACE monotherapy; 77 sessions) and 30 patients with 48 tumors treated with an ablation-based approach consisting of microwave ablation (MWA) alone or combined TACE and MWA (94 TACE sessions, 53 MWA sessions).
    Patients receiving ablation-based interventions demonstrated superior long-term survival outcomes compared to those treated with TACE monotherapy. Median overall survival reached 1.6 years (95% CI: 1.1–2.1) in the ablation cohort versus 0.5 years (95% CI: 0.2–0.9) in the TACE monotherapy cohort (log-rank χ² = 12.17, p < 0.001). The 1-, 3-, and 5-year survival rates were 70%, 23%, and 8% in the ablation group, whereas the TACE monotherapy group demonstrated survival rates of 20%, 10%, and 0%, with no patients in the monotherapy group surviving past 4.5 years. After adjusting for maximum lesion diameter, number of lesions, and histological subtype in a multivariable Cox regression model, TACE monotherapy remained independently associated with increased mortality (hazard ratio [HR]: 2.711, 95% CI: 1.363–5.391, p = 0.004).
    Locoregional chemotherapy regimens used for neoadjuvant downsizing showed comparable effectiveness on a per-lesion basis, with gemcitabine-based regimens achieving 12.6% downsizing and irinotecan-based regimens achieving 19.7% downsizing (p = 0.452). Across all 224 interventional procedures performed, safety records identified no major procedure-related complications or treatment-related deaths. The authors noted that treatment allocation was nonrandomized and guided by hepatic tumor burden, introducing potential confounding by indication, and that chemotherapeutic regimens were administered across different time periods.

    Key Takeaways

    • Ablation-based therapy (microwave ablation alone or combined with transarterial chemoembolization) significantly improved median overall survival to 1.6 years (95% CI: 1.1–2.1) compared to 0.5 years (95% CI: 0.2–0.9) with TACE monotherapy, yielding 1-, 3-, and 5-year survival rates of 70%, 23%, and 8% versus 20%, 10%, and 0% (p < 0.001).
    • In multivariable Cox proportional hazards analysis adjusted for tumor diameter, lesion count, and histological subtype, TACE monotherapy was an independent predictor of increased mortality compared to ablation-containing strategies (HR 2.711, 95% CI: 1.363–5.391, p = 0.004).
    • Across 224 total interventional sessions, no major procedure-related complications or treatment-related deaths were reported, while neoadjuvant tumor downsizing did not differ significantly between gemcitabine-based (12.6%) and irinotecan-based (19.7%) regimens (p = 0.452).
    Read the original sourceJournal of Clinical Medicine